ImageneBio, Inc. (IMA): auditor change — ImageneBio dismisses EY, appoints PwC as auditor effective Aug 2, 2025

ImageneBio, Inc.

Audit committee dismissed Ernst & Young LLP as independent auditor effective August 2, 2025.
No disagreements or reportable events occurred during EY's audit periods (2024, 2023 and interim).
PricewaterhouseCoopers LLP appointed as new auditor for fiscal year ending Dec 31, 2025.
PwC previously served as auditor of Inmagene Biopharmaceuticals prior to merger with ImageneBio.
EY's audit reports for 2024 and 2023 were unqualified, with no adverse opinions.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ImageneBio, Inc. engaged PricewaterhouseCoopers LLP as its auditor.

Action: engagement
Auditor: PricewaterhouseCoopers LLP

Exact text from the filing

On August 2, 2025, upon the approval of the Audit Committee, PricewaterhouseCoopers LLP ("PwC") was appointed as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ImageneBio, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: PricewaterhouseCoopers LLP

Exact text from the filing

dismissed Ernst & Young LLP ("EY") as the Company’s independent registered public accounting firm, with such dismissal to become effective on August 2, 2025

View on SEC.gov

7 auditor changes filed in the last 30 days. Browse all auditor changes →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-173626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.